151 related articles for article (PubMed ID: 29131153)
1. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Wais V; Kündgen L; Bohl SR; von Harsdorf S; Schlenk RF; Döhner K; Teleanu V; Bullinger L; Nguyen TM; Drognitz K; Moulin JC; Binnenhei M; Bentz M; Döhner H; Bunjes D; Kuchenbauer F; Ringhoffer M
Bone Marrow Transplant; 2018 Jan; 53(1):94-96. PubMed ID: 29131153
[No Abstract] [Full Text] [Related]
2. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J; Finke J; Ngoya M; Galimard JE; Craddock C; Raj K; Bloor A; Nicholson E; Eder M; Kim O; Valerius T; Snowden JA; Tholouli E; Crawley C; Collin M; Wilson KMO; Gadisseur A; Protheroe R; Wagner-Drouet EM; Savani BN; Spyridonidis A; Ciceri F; Nagler A; Mohty M
Bone Marrow Transplant; 2024 Feb; 59(2):247-254. PubMed ID: 38040842
[TBL] [Abstract][Full Text] [Related]
3. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
Chen GL; Hahn T; Wilding GE; Groman A; Hutson A; Zhang Y; Khan U; Liu H; Ross M; Bambach B; Higman M; Neppalli V; Sait S; Block AW; Wallace PK; Singh AK; McCarthy PL
Biol Blood Marrow Transplant; 2019 Apr; 25(4):689-698. PubMed ID: 30300731
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukaemia effect post fludarabine, melphalan and alemtuzumab reduced intensity allogeneic stem cell transplantat in HIV-infected patient with acute myeloid leukaemia.
Kanellopoulos A; Kaparou M; Xenou E; Paneesha S; Kishore B; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Bone Marrow Transplant; 2018 Dec; 53(12):1518-1521. PubMed ID: 30116019
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine/Melphalan 100 mg/m
Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
[TBL] [Abstract][Full Text] [Related]
7. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.
Marks R; Potthoff K; Hahn J; Ihorst G; Bertz H; Spyridonidis A; Holler E; Finke JM
Blood; 2008 Jul; 112(2):415-25. PubMed ID: 18451310
[TBL] [Abstract][Full Text] [Related]
8. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
Jain T; Alahdab F; Firwana B; Sonbol MB; Almader-Douglas D; Palmer J
Biol Blood Marrow Transplant; 2019 Apr; 25(4):728-733. PubMed ID: 30471339
[TBL] [Abstract][Full Text] [Related]
9. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.
Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K
Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836
[TBL] [Abstract][Full Text] [Related]
11. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
Kawamura K; Kako S; Mizuta S; Ishiyama K; Aoki J; Yano S; Fukuda T; Uchida N; Ozawa Y; Eto T; Iwato K; Kanamori H; Kahata K; Kondo T; Sawa M; Ichinohe T; Atsuta Y; Kanda Y
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2079-2087. PubMed ID: 28890406
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
14. Sequential reduced-intensity chemotherapy for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia with rare cytogenetic abnormalities transformed from Fanconi anemia.
Inoue A; Mori A; Yamazaki S; Suzuki R; Takitani K; Tamai H
Pediatr Int; 2018 Sep; 60(9):893-894. PubMed ID: 30255979
[No Abstract] [Full Text] [Related]
15. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Ciurea SO; Kongtim P; Varma A; Rondon G; Chen J; Srour S; Bashir Q; Alousi A; Mehta R; Oran B; Popat U; Hosing C; Olson A; Daver N; Konopleva M; Champlin RE
Blood; 2020 Feb; 135(6):449-452. PubMed ID: 31826244
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.
Popat U; de Lima MJ; Saliba RM; Anderlini P; Andersson BS; Alousi AM; Hosing C; Nieto Y; Parmar S; Khouri IF; Kebriaei P; Qazilbash M; Champlin RE; Giralt SA
Bone Marrow Transplant; 2012 Feb; 47(2):212-6. PubMed ID: 21423123
[TBL] [Abstract][Full Text] [Related]
17. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
20. BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Marchesi F; Capria S; Giannarelli D; Trisolini SM; Ansuinelli M; Caputo MD; Serrao A; Gumenyuk S; Renzi D; Pupo L; Palombi F; Provenzano I; Di Rocco A; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Cantonetti M; Mengarelli A
Bone Marrow Transplant; 2018 Aug; 53(8):1051-1054. PubMed ID: 29440737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
